---
title: "Oncology Institute to trade on Nasdaq as STLN from Aug. 4, replacing TOI"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294690393.md"
description: "The Oncology Institute has rebranded as Starling Oncology. Its Nasdaq trading ticker will change from TOI to STLN, effective August 4, 2026."
datetime: "2026-08-03T12:06:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294690393.md)
  - [en](https://longbridge.com/en/news/294690393.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294690393.md)
---

# Oncology Institute to trade on Nasdaq as STLN from Aug. 4, replacing TOI

-   The Oncology Institute rebranded as Starling Oncology. \* Nasdaq trading to switch to ticker STLN from TOI, effective Aug. 4, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Oncology Institute Inc. published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [TOI.US](https://longbridge.com/en/quote/TOI.US.md)
- [STLN.US](https://longbridge.com/en/quote/STLN.US.md)
- [TOIIW.US](https://longbridge.com/en/quote/TOIIW.US.md)

## Related News & Research

- [Major Investor Quietly Boosts Position in Oncology Powerhouse](https://longbridge.com/en/news/293546905.md)
- [Oncology Institute CMO Yale Podnos disposes of 23,452 common shares worth $150,362.95](https://longbridge.com/en/news/292961191.md)
- [Oncology Institute Refinances Debt with New Term Loan](https://longbridge.com/en/news/291980788.md)
- [Pfizer Q2 earnings on deck: What to expect](https://longbridge.com/en/news/294821640.md)
- [Celcuity says NCCN guidelines add newly FDA-approved REVTORPYK for advanced HR+/HER2- breast cancer](https://longbridge.com/en/news/294366586.md)